8-K: Biogen to Acquire Apellis for $5.6B, Boosting Immunology Portfolio

Biogen Inc. will acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right of up to $4.00 per share, expanding its immunology and rare disease footprint.

Summary

• Biogen Inc. (Parent) will acquire Apellis Pharmaceuticals, Inc. (Company) through a tender offer and subsequent merger.
• The offer price is $41.00 per share in cash, plus one contractual, non-transferable contingent value right (CVR) per share, potentially adding up to $4.00 in cash.
• The upfront equity consideration for the acquisition is approximately $5.6 billion.
• The offer price represents an 86% premium to Apellis's 90-day volume-weighted average stock price and a 35% premium to its 52-week high.
• CVRs are contingent on SYFOVRE and related products achieving annual global net sales of at least $1.5 billion (for $2.00 per CVR) and $2.0 billion (for an additional $2.00 per CVR) in specified calendar years between 2027 and 2031.
• The acquisition is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals.
• Apellis's key commercialized products, EMPAVELI and SYFOVRE, generated combined net sales of $689 million in 2025 and are expected to grow at a mid-to-high teens rate through at least 2028.
• Certain Apellis directors and executive officers, holding approximately 14% of outstanding shares, have entered into a Tender and Support Agreement to tender their shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for Apellis shareholders due to the significant upfront premium and potential for additional value through CVRs, while strategically strengthening Biogen's portfolio and future growth prospects.

Positives

• Apellis shareholders receive a significant upfront cash premium of 86% over the 90-day volume-weighted average stock price and 35% over the 52-week high.
• The contingent value rights (CVRs) offer potential for an additional $4.00 per share, providing further upside tied to SYFOVRE's commercial success.
• The acquisition immediately adds two commercialized, differentiated immunology and rare disease medicines (EMPAVELI and SYFOVRE) to Biogen's portfolio, enhancing its growth profile.
• EMPAVELI and SYFOVRE generated combined net sales of $689 million in 2025, providing immediate revenue, with expected growth in the mid-to-high teens through at least 2028.
• Apellis's established U.S. sales infrastructure and nephrology capabilities are expected to accelerate Biogen's commercial readiness for felzartamab, a Phase 3 kidney disease drug.
• The transaction is expected to be increasingly accretive to Biogen's Non-GAAP diluted EPS starting in 2027 and meaningfully increase its non-GAAP EPS compounded annual growth rate through the end of the decade.

Negatives

• The contingent value rights (CVRs) are non-transferable, limiting liquidity for holders.
• There is no assurance that the CVR milestones will be achieved, meaning the full potential value of $4.00 per CVR may not be realized.
• Apellis will be required to pay Biogen a termination fee of $205,000,000 under certain circumstances, such as if the Company accepts a superior proposal or changes its board recommendation.

Risks

• The transaction may not be completed in a timely manner, or at all, due to various factors including regulatory approvals or failure to satisfy closing conditions.
• Uncertainty exists regarding the timing or outcome of regulatory approvals or actions, which could include prohibitions, delays, or approvals subject to adverse conditions.
• There is a risk that the CVR milestones may never be achieved, resulting in no contingent consideration payments.
• The announcement or pendency of the transactions could negatively impact the trading price of Apellis or Biogen stock, or their business relationships with employees, collaborators, vendors, competitors, or governmental entities.
• Potential difficulties in retaining employees as a result of the transactions could disrupt business operations.
• Stockholder litigation or legal proceedings in connection with the transactions may result in significant costs of defense, indemnification, and liability, or affect the timing or certainty of closing.
• Changes in industry, market, economic, political, or regulatory conditions, future exchange and interest rates, and changes in tax laws could impact the anticipated benefits of the transactions.

Future Outlook

Biogen anticipates the acquisition will bolster its nearand long-term growth prospects, adding immediate revenue from two products with significant growth potential. The transaction is expected to be increasingly accretive to Biogen's Non-GAAP diluted EPS starting in 2027 and meaningfully increase its non-GAAP EPS compounded annual growth rate through the end of the decade. Biogen expects to finance the acquisition with a combination of cash and borrowings and aims to fully de-lever by the end of 2027, maintaining financial flexibility for future investments. Apellis plans to submit its application for SYFOVRE prefilled syringe (PFS) FDA approval in the first half of 2026. The first trial readout for Biogen's felzartamab is expected in the first half of 2027.

Management Comments

• Christopher A. Viehbacher, Biogen's President and CEO, stated, "This acquisition immediately advances Biogen's ongoing transformation. The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio and bolsters our near-and long-term growth potential."
• Viehbacher also commented, "We believe our combined capabilities and experience will allow us to maximize the potential of SYFOVRE and EMPAVELI, while Apellis talent, expertise and field capabilities will further strengthen Biogen, deepening the foundation for our growing nephrology franchise with felzartamab and serving many more patients with immune-mediated retinal disease."
• Cedric Francois, M.D., Ph.D., co-founder and CEO of Apellis, expressed, "I am incredibly proud of the Apellis team and what we have achieved, including bringing two transformational medicines – SYFOVRE and EMPAVELI – to patients and building an innovative pipeline leveraging our deep expertise in complement science."
• Francois added, "With Biogen's extensive experience with immunology and rare disease, we believe this transaction will accelerate our impact and enable us to reach more patients. This transaction represents a compelling outcome for our shareholders and a strong validation of our strategy, scientific innovation, and execution."

Industry Context

StockSavvy.ai notes that this acquisition positions Biogen to significantly strengthen its presence in the immunology and rare disease markets, particularly in complement-driven diseases. The addition of EMPAVELI and SYFOVRE provides immediate commercial products with strong growth trajectories, diversifying Biogen's revenue streams. Furthermore, Apellis's expertise and sales infrastructure in nephrology are strategically valuable, accelerating Biogen's entry into this therapeutic area and bolstering the launch readiness for its own Phase 3 kidney disease asset, felzartamab. This move reflects a broader industry trend of larger pharmaceutical companies acquiring specialized biotech firms to gain access to innovative therapies and expand into high-growth therapeutic segments.

Comparison to Industry Standards

• The 86% premium to the 90-day volume-weighted average stock price is a substantial premium, generally exceeding typical premiums seen in biotech acquisitions, which often range from 30-50%. This suggests Biogen sees significant strategic value and growth potential in Apellis's assets.
• The inclusion of CVRs is a common mechanism in biotech acquisitions to bridge valuation gaps and share future upside, particularly for assets with significant but uncertain sales potential, such as SYFOVRE. This structure aligns the interests of former Apellis shareholders with Biogen's commercial success of the acquired assets.
• The combined 2025 net sales of $689 million for EMPAVELI and SYFOVRE, with projected mid-to-high teens growth through 2028, indicates a strong commercial foundation, comparable to other successful rare disease and specialty product launches in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The filing acknowledges the possibility of stockholder litigation against Apellis or its directors/officers relating to the transactions. Apellis retains the right to control the defense and settlement, but Biogen will have the opportunity to participate and provide consent for settlement.

Related Party Transactions

• Certain current directors and executive officers of Apellis (Cedric Francois, Gerald Chan, Alec Machiels, Pascal Deschatelets) and Morningside Venture Investments, Ltd., a significant stockholder, entered into a Tender and Support Agreement with Biogen and Purchaser. These 'Support Stockholders' collectively own approximately 14% of the outstanding shares and agreed to tender all their shares in the Offer and vote in favor of the merger.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium and potential additional cash through CVRs, representing a compelling return on investment.
• Employees: A significant proportion of Apellis employees are expected to join Biogen. For one year post-merger, they will receive comparable base salary, target short-term cash incentives, and substantially comparable other benefits (excluding equity, defined benefit pensions, post-employment health/welfare, retention/change-in-control payments). Service credit will be recognized for new plans.
• Customers/Patients: The acquisition is expected to accelerate the impact and reach of Apellis's transformational medicines, SYFOVRE and EMPAVELI, through Biogen's extensive experience and resources in immunology and rare diseases.
• Management: Key executives and directors are incentivized through the transaction, including an Excise Tax Gross-Up Plan, and have committed to supporting the merger by tendering their shares.

Next Steps

• Purchaser to commence a tender offer within ten (10) Business Days after March 31, 2026.
• Tender offer to remain open for 20 business days, subject to extension.
• Parent and Company to make HSR Act filing within 15 business days after March 31, 2026.
• Promptly following consummation of the offer, Purchaser will merge with and into Apellis.
• Apellis plans to submit its application for SYFOVRE prefilled syringe (PFS) FDA approval in the first half of 2026.
• First trial readout for Biogen's felzartamab (Phase 3 kidney disease drug) expected in the first half of 2027.
• Biogen plans to update full year 2026 guidance when it reports earnings for the first quarter of 2026.

Key Dates

Recommendation

The acquisition offers a substantial premium of 86% over the 90-day volume-weighted average stock price and 35% over the 52-week high, providing a significant immediate return for Apellis shareholders. The inclusion of CVRs for up to an additional $4.00 per share offers further potential upside, aligning shareholder interests with the future commercial success of SYFOVRE. The unanimous approval by Apellis's board and the commitment from key stockholders to tender their shares de-risk the transaction, making it highly attractive for investors seeking a favorable exit.

Keywords

Apellis Pharmaceuticals, Biogen, Merger Agreement, Tender Offer, Acquisition, Contingent Value Rights, CVR, SYFOVRE, EMPAVELI, Geographic Atrophy, C3 Glomerulopathy, PNH, Immunology, Rare Disease, Nephrology, Biotechnology, Pharmaceuticals